目的 观察多西他赛联合顺铂治疗晚期非小细胞肺癌(non-small cell lung cancer,NSCLC)的临床疗效及其不良反应。方法 选取2012-05至2014-05有明确病理诊断的晚期NSCLC患者214 例,其中79例为一线化疗(一线组),135例为二线化疗(二线组),化疗方案均选取多西他赛(75 mg/m²,首日)联合顺铂(80 mg/m²,第1~3天),21 d为一疗程。定期检测相关化验。2个疗程后评价临床疗效和不良反应,并对一、二线组进行比较。结果 总有效率为25.23%。未出现完全缓解(CR)病例,两组有效率分别为31.64%、21.48%,无统计学差异(P=0.283)。不良反应主要为骨髓抑制和恶心、呕吐,血小板、白细胞减少等,出现Ⅲ/Ⅳ度骨髓抑制的患者23例,占总数10.75%。一线组和二线组Ⅲ/Ⅳ度血小板减少的发生率分别为2.53%和8.15%(P＜0.05),比较两组其他不良反应,未见统计学差异。结论 多西他赛联合顺铂治疗晚期NSCLC近期疗效较好,尤其对肝脏转移病灶疗效显著,不良反应可耐受。

Objective To study the efficacy and toxicities of docetaxel combined with cisplatin in the treatment of patients with advanced non-small cell lung cancer (NSCLC). Methods 214 patients with advanced NSCLC confirmed pathlogically and/or cytologically from May 2012 to May 2014 were divided into two groups, group one (n=79) received first-line chemotherapy, the other group (group two, n=135) received second-line chemotherapy. The two groups were given docetaxel 75 mg/m², D1; plus cisplatin 80 mg/m², D1-3. The process was repeated every 3 weeks. The efficacy and toxicities were assessed after 2 cycles. Results The total efficacy was 25.23%. The two groups had no CR patient. The effective rate in the two groups were 31.64% and 21.48% respectively (P=0.283). The major toxicity was myelosuppression, nausea and vomiting. The III/IV° myelosuppression was 10.75%. The serious reduction rates of platelets in the two groups were 2.53% and 8.15%, respectively(P＜0.05). There was no other obviously different side effects in the two groups. Conclusions The combined chemotherapy of docetaxel with cisplatin is effective in the treatment of advanced NSCLC patient,especially in liver metastasis, and toxicities are tolerable.